Dahlrot 2018 (NS cohort).

Study characteristics
Study design	Cohort
Study setting	Setting: Nordic study (validation cohort) Country: Denmark Dates: diagnosis between January 2003 and May 2008.
Selection of participants	People included in a collaborative Nordic Study (NS) with WHO grade 3 and 4 gliomas treated with radiotherapy and different combinations of TMZ. Minimum 15 mm2 vital tumour tissue was required for inclusion.
Participant characteristics	Sample size: 92 (deaths: 64) Age: NR Sex: 57% men KPS: median NR ECOG performance status: 0–1: 64 (94%); 2: 4 (6%)
Tumour characteristics	GBM: 100% First diagnosis: 100% Biopsy: NR; subtotal resection: NR; total resection: NR IDH1 wild‐type: 94%; IDH2 wild‐type: NR
Treatment regimen	Radiotherapy and different combinations of TMZ
MGMT promoter methylation tests implemented	PSQ, DIF
Dates and follow‐up	Timing of MGMT assessment: NR Start time for follow‐up: date of randomisation; follow‐up: median 17.5; range 0.5–129 months
Notes